Dianthus Therapeutics, Inc. (DNTH)
NASDAQ: DNTH · Real-Time Price · USD
21.55
+0.10 (0.47%)
Apr 29, 2025, 4:00 PM EDT - Market closed
Company Description
Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases.
The company’s lead novel and proprietary monoclonal antibody product candidate includes DNTH103, a human monoclonal immunoglobulin G4 with picomolar that binds the active form of C1s, which is in clinical-stage trials for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.
Dianthus Therapeutics, Inc. was founded in 2019 and is headquartered in New York, New York.
Dianthus Therapeutics, Inc.
| Country | United States |
| Founded | 2015 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 78 |
| CEO | Marino Garcia |
Contact Details
Address: 7 Times Square, 43rd Floor New York, New York 10036 United States | |
| Phone | 929 999 4055 |
| Website | dianthustx.com |
Stock Details
| Ticker Symbol | DNTH |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001690585 |
| CUSIP Number | 252828108 |
| ISIN Number | US2528281080 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Marino Garcia M.B.A. | President, Chief Executive Officer and Director |
| Ryan Savitz | Chief Financial Officer and Chief Business Officer |
| Simrat Randhawa M.B.A., M.D. | Chief Medical Officer |
| Edward G. Carr | Chief Accounting Officer |
| Judson Taylor | Senior Vice President and Head of Technical Operations |
| Jennifer Davis Ruff | Vice President and Head of Investor Relations and Corporate Affairs. |
| Adam M. Veness Esq. | Senior Vice President, General Counsel and Secretary |
| Kristina Maximenko | Chief People Officer |
| Rashieda Gluck | Head of Clinical Development Operations |
| Scott Nogi M.B.A. | Head of Business Operations |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 24, 2025 | SCHEDULE 13G/A | Filing |
| Apr 17, 2025 | SCHEDULE 13G | Filing |
| Apr 10, 2025 | ARS | Filing |
| Apr 10, 2025 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 10, 2025 | DEF 14A | Other definitive proxy statements |
| Mar 24, 2025 | SCHEDULE 13G | Filing |
| Mar 19, 2025 | SCHEDULE 13D/A | Filing |
| Mar 11, 2025 | S-8 | Securities to be offered to employees in employee benefit plans |
| Mar 11, 2025 | 10-K | Annual Report |
| Mar 11, 2025 | 8-K | Current Report |